Hiral Aghara

Ms. Hiral Aghara

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Mediators of Inflammation
Verified
Journal Article
Open access
HAHiral Aghara
Hiral Aghara
MPManali Patel
Manali Patel
PCPrashsti Chadha
Prashsti Chadha
KPKirti Parwani
Kirti Parwani
RCRuchi Chaturvedi
Ruchi Chaturvedi
PALASH MANDALPALASH MANDAL
PALASH MANDAL
The gut–liver–brain axis (GLB axis) plays a crucial role in maintaining metabolic, immune, and neurological homeostasis. The gut microbiota influences systemic health through its metabolites, including short‐chain fatty acids (SCFAs), bile acids (BAs), and tryptophan (Trp) derivatives, which regulate immune function, lipid metabolism, and neurotransmitter balance. Dysbiosis is an imbalance in gut microbiota that has been implicated in metabolic dysfuntion associated fatty liver disease (MAFLD), alcohol‐associated liver disease (AALD), and neuroinflammatory conditions such as schizophrenia. Increased gut permeability allows microbial byproducts like lipopolysaccharides (LPSs) to enter the liver and brain, activating inflammatory pathways that contribute to disease progression. Moreover, hepatic dysfunction can lead to neuroinflammation and cognitive impairments. Understanding the interplay between microbial metabolites and host physiology provides insight into novel therapeutic interventions. Strategies such as probiotics, prebiotics, synbiotics, fecal microbiota transfer (FMT), and postbiotics offer potential treatments to restore gut eubiosis and mitigate disease severity. This review highlights the mechanistic role of the GLB axis in health and disease, emphasizing microbiome‐targeted therapies as a promising avenue for managing metabolic and neuropsychiatric disorders. Trial Registration: ClinicalTrials.gov identifier: NCT04823676, NCT02496390, NCT06024681, NCT02721264

2 July 2024 in Gastroenterology Insights
Verified
Journal Article
Open access
PDF file
HAHiral Aghara
Hiral Aghara
PCPrashsti Chadha
Prashsti Chadha
PALASH MANDALPALASH MANDAL
PALASH MANDAL
Alcoholic liver disease (ALD) develops when the immunotolerant environment of the liver is compromised due to excessive alcohol consumption. ALD progression involves variations in the expressions of multiple genes, resulting in liver inflammation and the development of a leaky gut. It is still unclear which molecular mechanism is involved in ALD progression, and due to that, there are currently no FDA-approved drugs available for its treatment. In this study, the protective effects of graphene oxide (GO) nanoparticles were investigated against ethanol-induced damage in the gut–liver axis in in vitro. GO was synthesized using a modified Hummer’s method, and characterization was performed. Given the general concerns regarding nanoparticle toxicity, assessments of cell viability, lipid accumulation, DNA damage, cell death, and the generation of reactive oxygen species (ROS) were conducted using various techniques. Furthermore, the gene expressions of pro- and anti-inflammatory cytokines were determined using RT-qPCR. The findings reveal that GO promoted cell viability even against ethanol treatment. Additionally, lipid accumulation significantly decreased when cells were treated with GO alongside ethanol compared to ethanol treatment alone, with similar trends observed for other assays. A gene expression analysis indicated that GO treatment reduced the expression of proinflammatory cytokines while enhancing the expression of antioxidant genes. Moreover, GO treatment led to improvements in gut integrity and a reduction in proinflammatory cytokines in colon cells damaged by ethanol. These findings suggest that GO holds promise as a drug carrier, exhibiting no observed toxic effects. By shedding light on the protective effects of GO against ethanol-induced damage, this study contributes to the burgeoning field of nanoparticle-mediated therapy for ALD.

9 July 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HAHiral Aghara
Hiral Aghara
SSSimran Samanta
Simran Samanta
MPManali Patel
Manali Patel
PCPrashsti Chadha
Prashsti Chadha
DPDivyeshkumar kanubhai Patel
Divyeshkumar kanubhai Patel
PALASH MANDALPALASH MANDAL
PALASH MANDAL
Background: Alcohol-associated liver disease (ALD) is a primary global health concern, exacerbated by oxidative stress, inflammation, and gut barrier dysfunction. Conventional phytocompounds exhibit hepatoprotective potential but are hindered by low bioavailability. This study aimed to evaluate the hepatoprotective and gut-barrier-restorative effects of green-synthesized silver nanoparticles (AgNPs) derived from Enicostemma littorale, a medicinal plant known for its antioxidant and anti-inflammatory properties. Methods: AgNPs were synthesized using aqueous leaf extract of E. littorale and characterized using UV-Vis, XRD, FTIR, DLS, and SEM. HepG2 (liver) and Caco-2 (colon) cells were exposed to 0.2 M ethanol, AgNPs (1–100 µg/mL), or both, to simulate ethanol-induced toxicity. A range of in vitro assays was performed to assess cell viability, oxidative stress (H2DCFDA), nuclear and morphological integrity (DAPI and AO/EtBr staining), lipid accumulation (Oil Red O), and gene expression of pro- and anti-inflammatory, antioxidant, and tight-junction markers using RT-qPCR. Results: Ethanol exposure significantly increased ROS, lipid accumulation, and the expression of inflammatory genes, while decreasing antioxidant enzymes and tight-junction proteins. Green AgNPs at lower concentrations (1 and 10 µg/mL) restored cell viability, reduced ROS levels, preserved nuclear morphology, and downregulated CYP2E1 and SREBP expression. Notably, AgNPs improved the expression of Nrf2, HO-1, ZO-1, and IL-10, and reduced TNF-α and IL-6 expression in both cell lines, indicating protective effects on both liver and intestinal cells. Conclusions: Green-synthesized AgNPs from E. littorale exhibit potent hepatoprotective and gut-barrier-restoring effects through antioxidant, anti-inflammatory, and antilipidemic mechanisms. These findings support the therapeutic potential of plant-based nanoparticles in mitigating ethanol-induced gut–liver axis dysfunction.

10 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
HAHiral Aghara
Hiral Aghara
SSSimran Samanta
Simran Samanta
MPManali Patel
Manali Patel
PCPrashsti Chadha
Prashsti Chadha
DPDivyesh Patel
Divyesh Patel
PALASH MANDALPALASH MANDAL
PALASH MANDAL
Background: Alcohol-associated liver disease (ALD) is a primary global health concern, exacerbated by oxidative stress, inflammation, and gut barrier dysfunction. Conventional phytocompounds exhibit hepatoprotective potential but are hindered by low bioavailability. This study aimed to evaluate the hepatoprotective and gut barrier-restorative effects of green-synthesized silver nanoparticles (AgNPs) derived from Enicostemma littorale, a medicinal plant known for its antioxidant and anti-inflammatory properties. Methods: AgNPs were synthesized using aqueous leaf extract of E. littorale and characterized by UV-Vis, XRD, FTIR, DLS, and SEM. HepG2 (liver) and Caco-2 (colon) cells were exposed to 0.2 M ethanol, AgNPs (1–100 µg/mL), or both, to simulate ethanol-induced toxicity. A range of in vitro assays was performed to assess cell viability, oxidative stress (H₂DCFDA), nuclear and morphological integrity (DAPI and AO/EtBr staining), lipid accumulation (Oil Red O), and gene expression of pro- and anti-inflammatory, antioxidant, and tight junction markers using RT-qPCR. Results: Ethanol exposure significantly increased ROS, lipid accumulation, and expression of inflammatory genes, while decreasing antioxidant enzymes and tight junction proteins. Green AgNPs at lower concentrations (1 &10 µg/mL) restored cell viability, reduced ROS levels, preserved nuclear morphology, and downregulated CYP2E1 and SREBP expression. Notably, AgNPs improved the expression of Nrf2, HO-1, ZO-1, and IL-10, and reduced TNF-α and IL-6 expression in both cell lines, indicating protective effects on both liver and intestinal cells. Conclusions: Green-synthesized AgNPs from E. littorale exhibit potent hepatoprotective and gut barrier-restoring effects through antioxidant, anti-inflammatory, and antilipidemic mechanisms. These findings support the therapeutic potential of plant-based nanoparticles in mitigating ethanol-induced gut–liver axis dysfunction.

1 January 2026 in Mediators of Inflammation
Verified
Journal Article
Open access
MPManali Patel
Manali Patel
HAHiral Aghara
Hiral Aghara
PCPrashsti Chadha
Prashsti Chadha
HSHarshrajsinh Solanki
Harshrajsinh Solanki
DSDhrubjyoti Sharma
Dhrubjyoti Sharma
PALASH MANDALPALASH MANDAL
PALASH MANDAL
Chronic ethanol exposure activates inflammatory signaling pathways and inflicts hepatocellular damage, leading to alcohol‐associated liver diseases (ALDs). ALD is one of the major causes of global burden, yet there are no FDA‐approved treatment options available. This study evaluates the hepatoprotective effects of short‐chain fatty acids (SCFAs), mainly sodium acetate (NaA) and sodium butyrate (NaB), against ethanol‐induced inflammation and oxidative stress in both in vitro (Buffalo Rat Liver‐3A [BRL3A]) and in vivo (male Wistar rats) models. The treatment of NaA and NaB and their combination was given to the cell lines where maximum viability was observed at concentrations of 1.5 mM, 5 mM, and 0.1 mM + 1 mM, respectively. Additionally, reactive oxygen species (ROS) and nuclear morphology were assessed by fluorescent staining. For in vivo samples, the hepatic injury was analyzed by serum biochemical markers. Furthermore, hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) staining were employed, which provided structural and immunological alterations in hepatic tissue. RT‐qPCR profiled the expression levels of various pro‐inflammatory and anti‐inflammatory cytokines, as well as cytochrome P450 E1 (CYP2E1) and antioxidative stress markers. Moreover, enzyme‐linked immunosorbent assay (ELISA) quantified the essential protein targets such as TNF‐α, MCP‐1, IL‐1β, IL‐6, HO‐1, and Nrf2. The administration of NaA, NaB, and their combination resulted in reduced ROS levels and expression of pro‐inflammatory cytokines, preserved nuclear integrity, and neutrophil infiltration. These findings were further confirmed by in silico analysis and conserved amino acid interactions, and the affinities of NaA and NaB for TNF‐α and MCP‐1 were observed as compared to established inhibitors or activators. This study is the first demonstration to report the synergistic effects of NaA and NaB on the feedback loop of the nuclear factor kappa B (NF‐κB) signaling pathway, suggesting their potential as promising therapeutic candidates for alleviating alcohol‐induced hepatic damage.

6 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
HAHiral Aghara
Hiral Aghara
TSTeja Naveen Sata
Teja Naveen Sata
PCPrashsti Chadha
Prashsti Chadha
MPManali Patel
Manali Patel
ISIsmail
Ismail
PALASH MANDALPALASH MANDAL
PALASH MANDAL
Alcohol-associated liver disease (ALD) is driven by complex interactions among hepatic lipid accumulation, oxidative stress, inflammation, cell death, and disruption of the gut–liver axis. Therapeutic strategies capable of targeting multiple interconnected pathogenic pathways remain limited. In this study, we investigated the protective potential of graphene oxide nanoparticles (GNPs) in a chronic ethanol-fed rat model of ALD. Male Wistar rats were subjected to ethanol feeding and intermittently treated with GNPs (10 mg/kg) by oral gavage. Hepatic injury was assessed by biochemical parameters, histology, lipid accumulation, gene and miRNA expression, protein analysis, and gut microbiome profiling. Ethanol feeding induced hepatic steatosis, oxidative stress, apoptotic and necroptotic signaling, intestinal barrier disruption, gut dysbiosis, and activation of hepatic inflammatory pathways. GNP treatment markedly attenuated ethanol-induced lipid accumulation, normalized liver morphology, and reduced biochemical markers of liver injury. These effects were accompanied by restoration of antioxidant defenses, including Nrf2 and HO-1, and suppression of CYP2E1 expression and cell death–associated markers. In parallel, GNPs preserved intestinal architecture, maintained tight junction gene expression, and suppressed intestinal inflammatory responses. Gut microbiome analysis revealed partial restoration of ethanol-induced dysbiosis, including recovery of beneficial postbiotic-associated bacterial taxa. Improved intestinal homeostasis was associated with attenuation of hepatic TLR4-associated inflammatory signalling and modulation of macrophage-associated markers. Furthermore, GNP treatment partially normalized ethanol-induced dysregulation of miRNAs implicated in lipid metabolism, inflammation, and oxidative stress. Collectively, these findings demonstrate that GNPs exert a coordinated protective effect against ethanol-induced liver injury by modulating multiple pathological processes along the gut–liver axis. This multi-targeted activity highlights the therapeutic potential of graphene oxide nanoparticles as an intervention strategy for early-stage alcohol-associated liver disease.